Financial Report

 

Labor Report

 



AB Wilh. Becker
Financial Benchmark: Methodology and Excerpt

Home        
AB Wilh. Becker
Financial Benchmark: Methodology and Excerpt


Audience: designed for financial managers, directors, CFOs, strategic planners
Author:Philip M. Parker, Professor, INSEAD
Price: $210
Pages: 310 pp
Published:
Order Online
Order Via Fax

Table of Contents

ABOUT THE AUTHOR(S)

ABOUT ICON GROUP LTD.

 

 

Methodology/Excerpt

INTRODUCTION & METHODOLOGY

WHAT DOES THIS REPORT COVER?

With the globalization of markets, greater foreign competition, and the reduction of entry barriers, it becomes all the more important to benchmark a company’s financial indicators against other firms on a worldwide basis. This report reflects to two inescapable trends: (1) a return to fundamentals, and (2) globalization. World stock markets have recently witnessed a return to fundamental financial analysis. Sound management as opposed to “hype” will in the long run generate shareholder value. This philosophy has lead to a greater emphasis on financial fundamentals and benchmarking. Not benchmarking in a traditional sense, but benchmarking at the global level as markets become all the more international and firms create transnational and global strategies. How does a firm's asset structure vary compared to global benchmarks? Does it hold more cash and other short term assets, or does it concentrate its assets in physical plant and equipment? On the liability side, does a company have a higher percent of payables compared to the benchmarks, or does it hold a higher concentration of long-term debt? The structure of the income statement is more telling. Does the firm have a relatively higher costs of goods sold, operating costs, or income taxes compared to its global benchmarks? Are their returns on equity higher? Are profit margins greater? Are inventories held longer?

While these are the classic questions raised in most graduate MBA courses on managerial finance, in a globalizing economy the method to answer these questions may not be simple. If we consider that an industry spans multiple countries, continents and currencies, how can one perform benchmarking? This report does so by going beyond traditional analyses by considering companies competing in the same or similar industrial classification at a global level. Doing so, however, is not an obvious task. First, one needs to find firms competing in the same sector, but not necessarily competing directly with the company in local markets. These firms should not be perceived, therefore, to be direct competitors to the company in question, but simply those that have been classified by various sources (e.g. EDGAR or similar foreign filings), as competing to serve customers in the same link of the value chain, or broad industrial classification, as identified by SIC, NAICS or similar codes. Second, given the international nature of the task, one needs to control for exchange rate volatility. Finally, one needs use reasonably comparable financial line items or standards.

The goal of this report is to save the reader time. It is designed to assist consultants, financial managers, strategic planners, and corporate officers in gauging indicators of a company’s financial structure compared to firms competing or participating in the same economic sector, at the global level. AB Wilh. Becker, is it financially competitive? There is no absolute answer to this question. This report is not about whether a particular company or industry has performed well or poorly in the past or will do so in the future. Such conclusions are left to the reader. AB Wilh. Becker neither sponsored nor endorsed the analysis that follows.

METHODOLOGY

This report analyzes deviations between AB Wilh. Becker (HOGANAS, Sweden) and international industrial benchmarks. Based on the methodology described below, the following chapters report a common-size statement or vertical analysis of AB Wilh. Becker vis-à-vis global benchmarks. In contrast to this report, most vertical analyses focus on benchmarking against domestic ratios, often published by government agencies or commercial sources (e.g. Value Line, Dun and Bradstreet, and Standard & Poor’s). This type of analysis is commonly conducted by creditors, prospective investors, chief financial officers, lenders, and a corporation’s strategic management team. For those unfamiliar with this type of analysis, frequently taught in graduate schools of business, the reader is recommended Jae K. Shim and Joel G. Siegel’s recent book titled Financial Management. In their discussion of financial statement analysis and ratios, Skim and Siegel (p. 42-43), describe common-size statement (vertical analysis) as follows:

A common-size statement is one that shows each item in percentage terms. Preparation of common-size statements is known as vertical analysis, in which a material financial statement item is used as a base value and all other accounts on the financial statement are compared to it. In the balance sheet, for example, total assets equal 100 percent, and each individual asset is stated as a percentage of total assets. Similarly, total liabilities and stockholders’ equity are assigned a value of 100 percent and each liability or equity account is then stated as a percentage of total liabilities and stockholders’ equity, respectively. … For the income statement, a value of 100 percent is assigned to net sales, and all other revenues and expense accounts are related to it. It is possible to see at a glance how each dollar of sales is distributed among various costs, expenses, and profits.

The authors suggest that vertical analyses involve industry-based comparisons. Such a comparison “allows you to answer the question, ‘How does a business fare in the industry?’ You must compare the company’s ratios to… industry norms.” (p. 43-44)

In this report, I calculate an industry norm by looking at firms at the global level, as opposed to a local level. In what follows, I will describe the seven-stage methodology used in performing this analysis. Each stage should be seen as a working assumption behind the numbers presented in later chapters.

Stage 1. Industry Classification. This stage begins by classifying the company into an industry. For this, I have relied on a combination of the North American Industry Classification System (NAICS pronounced “Nakes”), a relatively new system for classifying business establishments, and the older Standard Industrial Classification (SIC) system.  Adopted in 1997, NAICS codes are the new industry classification codes used by statistical agencies of the United States. NAICS was developed jointly by the U.S., Canada, and Mexico to provide comparability in statistics about business activity across North America. After 60 years of service, the outdated SIC system was retired on October 1, 2000, leaving only the NAICS codes for official use. The NAICS classification system adds some 350 new industries and represents a revision to over 60% of the previous SIC industries. Despite its official retirement, the SIC system is still commonly used (and often reported in firm’s financial statements).

For most companies in the world, classification within either the new NAICS or older SIC systems is a rather straight forward exercise. For some, however, it can be problematic. This is true for several reasons. The first being that the SIC or NAICS classification systems are rather broad for many product and industry categories (a firm’s products or services may be only a minor aspect of the classification’s definition). The second is that some firms’ activities span multiple codes. Finally, it is possible that a firm is classified by one source using its SIC code, and by another using its NAICS code, and by a third using both. Furthermore, some sources do not report either code, but instead use qualitative statements of the firm’s activities. Nevertheless, if one wishes to pursue a vertical analysis, some classification needs to take place which selects a peer group. In making this classification, one can rely on a number of sources. In some countries, firms must “self” classify in official periodic reports (e.g. annular reports, 10Ks, etc.) to public authorities (such as the Securities and Exchange Commission). These reports are then open for public scrutiny (e.g. EDGAR filings). In other cases, commercial data vendors or private research firms provide SIC/NAICS codes for specific companies. These include:

  • Bloomberg - www.bloomberg.com

  • Datastream (Thomson Financial) - www.datastream.com

  • Dun & Bradstreet - www.dnb.com

  • Hoovers - www.hoovers.com

  • InfoUSA - www.infousa.com

  • Investext (Thomson Financial) - www.investext.com

  • Kompass International Neuenschwander SA. – www.kompass.com

  • Primark (Thomson Financial) - www.primark.com

  • Profound (The Dialog Corporation – A Thomson Company) - www.profound.com

  • Reuters - www.reuters.com

  • Standard & Poor's - www.standardandpoors.com

It is interesting to note that commercial vendors often report different qualitative descriptions and industrial classifications from one to another. These descriptions and classifications may also be different from those reported by the firm itself. Anyone hoping to perform a benchmarking study, therefore, has to make a judgment call across these various sources in order to determine a reasonable classification. In this report, I have decided a meta-analytic process, by combining various sources (including linking a classification’s keywords to qualitative descriptions of the firm’s product line). In cases of inconsistency, the most recent or globally comparable available is chosen. Again, the overall goal is to classify firms, which either produce similar products, offer similar services, or are in the same stage of the value chain for a particular industrial classification. In the case of this report, the SIC code selected is: 28 which is defined as “Chemicals and Allied Products Manufacturing”. This classification should be seen as a working assumption. In order to obtain a more detailed discussion of this classification, the reader is referred to the web sites developed by the U.S. Census Bureau: http://www.census.gov/epcd/www/naics.html. Basic definitions and descriptions are provided at: http://www.census.gov/epcd/www/drnaics.htm#q1. A full correspondence table between SIC and NAICS codes, and detailed definitions are given at http://www.census.gov/epcd/www/naicstab.htm.

Stage 2. Firm-level Data Collection. A global search is conducted across over 20,000 companies in over 40 major economies for those that (1) may be included in the classification from Stage 1, and (2) report financials (balance sheet and income statements). It should be noted that the public-domain financials can be either historic or projections. It should also be noted that even historic figures can be modified in the future and often represent “estimates” of performance.

Stage 3. Standardization. Once collected, public domain financial figures of firms identified in Stage 2 are standardize into comparable categories (assets, liabilities, and income). From there, we eliminate all currency effects by standardizing within each category (creating ratios). In order to maintain comparability over time and across companies and countries, vertical analysis is used. In the case of a firm’s assets, I treat the total assets as equaling 100, irrespective of the value of the local currency. All other assets are then calculated as a percent of total assets. In this way, the structure of the firm’s assets can be easily interpreted and compared with international benchmarks. For liabilities, total liabilities and equity are indexed to equal to 100. For the income statement, total revenue is indexed to equal 100, and all other figures are calculated as a percent of these figures.

Stage 4. Filtering. Not all the firms selected in Stage 2 or the ratios calculated in Stage 3 are used for the global benchmarks, as a number of companies are purposely dropped from the analysis, even though they may fall within the classification. This is justified by the “outlier” phenomenon that plagues such analysis. The problem lies in that any given company in the benchmarking pool may be facing some exceptional event or may be organized in an exceptional way so as to make its ratios vastly different from others in the same classification. By including such firms, the global benchmarks can be overly skewed. In many countries, firms are organized into holding groups. These groups nominally have very few employees (e.g. 4 to 25 employees), but have extremely large assets, liabilities, or revenues. As such, the inclusion or exclusion of firms having this form of management can affect the ratios and benchmarks reported. Likewise, some firms have no net sales, no assets, no liabilities, or ratios. Others have ratios that appear implausible for a normal or viable company. In order to not allow these firms to affect the global benchmarks, I have attempted to choose only those firms with reasonable financials. Finally, in some countries, detailed financials are not available or are not comparable to either the company in question or the global norm (e.g. various forms of depreciation). In this case, only those which exist and are comparable are reported. The details, therefore, that comprise a given ratio or set of ratios may not be reported. This may lead to the addition of several ratios, not summing to the whole.

Stage 5. Calculation of Global Norms. Once the filtering process has eliminated outliers, a final list of companies included in the global averages is compiled. In this report, the following companies are included (country of headquarters in parentheses, exchanges, and ticker symbols); again this list should be seen as a working assumption:

Company (Country)

Exchange

Ticker

Abbott Laboratories (USA)

NYSE, BSE, CIN, MSE,

ABT

Abbott Laboratories (Pakistan) Ltd (Pakistan)

BOM

Achilles Corporation (Japan)

OSA, TYO

5142

AECI Limited (South Africa)

JNB

AFE

Agis Industries Ltd. (Israel)

TEL

AGIS

Agrium Incorporated (Canada)

TOR, OTH

AGU

Air Liquide (France)

FRA, PAR, OTH

AI

Air Liquide Japan, Ltd. (Japan)

TYO

4086

Air Products and Chemicals Inc. (USA)

NYSE

APD

Air Water Inc. (Japan)

TYO

4088

Akzo Nobel N.V. (Netherlands)

AMS, BRU, FRA, GVA,

AKZ

Albemarle Corporation (USA)

NYSE

ALB

Alberto-Culver Company (USA)

NYSE, BSE, MSE, PBW

ACV A

Ales Groupe (France)

PAR

PHY

Allergan, Inc (USA)

NYSE

AGN

ALPharma Incorporated. (USA)

NYSE, MSE, PBW

ALO

Altana AG (Germany)

DUS, FRA, OTH

ALT

Amersham P.L.C. (United Kingdom)

LON

NAM

Amgen Incorporated (USA)

NAS

AMGN

Arab Potash Company (Jordan)

OTH

APOT

Arch Chemicals Incorporated (USA)

NYSE, BSE, CIN, MSE,

ARJ

Arisawa Mfg. Co., Ltd. (Japan)

TYO

5208

Asahi Denka Kogyo K.K. (Japan)

TYO

4401

Ascot Plc (United Kingdom)

LON

AST

Asia Chemical Corp (Taiwan)

TAI

T1715

Asian Paints (India) Limited (India)

OTH

Asklia Holding AG (Switzerland)

OTH

ASKN

AstraZeneca PLC (United Kingdom)

LON

AZN

Auriga Industries A.S. (Denmark)

CPH

AURI-B

Aventis Pharma Ltd. (India)

OTH

Aventis Pharma Pakistan Ltd. (Pakistan)

KAR

Banyu Pharmaceutical Co Ltd (Japan)

TYO

4515

Barr Laboratories Inc. (USA)

NYSE

BRL

BASF Aktiengesellschaft (Germany)

AMS, BRU, DUS, FRA,

BAS

Bayer (India) Limited (India)

BOM

Bayer Indonesia Tbk. P.T. (Indonesia)

JAK

BYSP

Beiersdorf AG (Germany)

OTH

BEI

Biocel a.s. (Czech Republic)

PRG

Bioglan Pharma plc (United Kingdom)

LON

BGP

Biotest AG (Germany)

FRA

BIO3

Blagden plc (United Kingdom)

BLAG

Boiron SA (France)

OTH

BOI

BorsodChem Rt. (Hungary)

OTH

Boryszew S.A. Chemical and Plastic Works (Poland)

WAR

BORYSZEW

Boryung Pharmaceutical Co. Ltd. (South Korea)

SEO

03850

Bristol-Myers Squibb Co (USA)

NYSE, BSE, CIN, MSE,

BMY

British Vita PLC (United Kingdom)

LON

BVIT

Buckeye Technologies Inc. (USA)

NYSE

BKI

C.I. Kasei Company, Limited (Japan)

TYO

7909

Cabot Corporation (USA)

NYSE, BSE, MSE, PCS

CBT

Cambrex Corporation (USA)

NYSE

CBM

Capro Corp. (South Korea)

SEO

63800

Carter-Wallace, Inc. (USA)

NYSE, BSE, MSE, PBW

CAR

CEA-Industrie SA (France)

PAR

CEI

Celanese AG (Germany)

FRA

CZZ

Cemedine Co., Ltd. (Japan)

OSA, TYO

4999

Century Enka Ltd. (India)

BOM

Cheil Industries Inc. (South Korea)

SEO

01300

ChemFirst Inc. (USA)

NYSE, BSE, MSE, PBW,

CEM

Chemical Company of Malaysia Berhad (Malaysia)

KUL, SIN

CLMS

Chong Kun Dang Pharmaceutical Corporation (South Korea)

SEO

01630

Choong Wae Pharmaceutical (South Korea)

SEO

01060

Christian Hansen Holding Aktieselskab (Denmark)

CPH

CHRH-B

Chugai Pharmaceutical Co Ltd (Japan)

OSA, TYO, OTH

4519

Church & Dwight Co Inc (USA)

NYSE

CHD

Ciba Specialty Chemicals Holding Inc.(CIBA) (Switzerland)

OTH, ZHR

CIBN

Clariant AG (Switzerland)

GVA, OTH, ZHR

CLN

Clarins (France)

PAR

CLR

Companhia Petroquimica do Sul (Brazil)

RIO, SOP

CPS3

Corporacao Industrial do Norte, S.A. (Portugal)

LIS

CIN

Cosway Corporation Berhad (Malaysia)

KUL

SMBM

Croda International Plc (United Kingdom)

LON

CRDA

Cytec Industries Inc. (USA)

NYSE

CYT

Daicel Chemical Industries Ltd (Japan)

OSA, TYO, OTH

4202

Dai-ichi Kogyo Seiyaku Co., Ltd. (Japan)

OSA, TYO, OTH

4461

Daiichi Pharmaceutical Co., Ltd. (Japan)

OSA, TYO

4505

Dainichiseika Colour & Chemicals Mfg. Co., Ltd. (Japan)

TYO

4116

Dainippon Ink & Chemicals Inc (Japan)

OSA, TYO, OTH

4631

Dainippon Pharmaceutical Co Ltd (Japan)

OSA, TYO, OTH

4506

Daiso Co., Ltd. (Japan)

OSA, TYO, OTH

4046

Dankos Laboratories Tbk. Pt. (Indonesia)

JAK

DNKS

Dawood Hercules Chemicals Limited (Pakistan)

KAR

DC Chemical Company Limited (South Korea)

SEO

10060

Del Laboratories, Inc. (USA)

ASE

DLI

Delta Electrical Industries Ltd (South Africa)

JNB

DEL

Delta PLC (United Kingdom)

LON

DLTA

Denki Kagaku Kogyo Kabushiki Kaisha (Japan)

OSA, TYO, OTH

4061

Dial Corporation (USA)

NYSE

DL

Dong-A Pharmaceutical Company Limited (South Korea)

SEO

00640

Dongbu Hannong Chemical Co. Ltd. (South Korea)

SEO

00990

DPI Co. Ltd. (South Korea)

SEO

00320

DSM NV (Netherlands)

AMS, DUS, FRA, GVA,

DSM

Du Pont Canada Inc (Canada)

MON, TOR

DUP A

Dyno ASA (Norway)

DYN

E. Merck (India) Limited (India)

BOM

EMRK

E.I. Du Pont De Nemours & Co (USA)

NYSE, BSE, CIN, MSE,

DD

Eastman Chemical Co (USA)

NYSE

EMN

Ecolab Inc (USA)

NYSE, MSE, PBW

ECL

Eczacibasi Ilac Sanayi ve T.A.S. (Turkey)

IST

ECILC

Egis Gyogyszergyar Reszvnytarsas A.G. (Hungary)

BUD

Egyptian Financial and Industrial Co. (Egypt)

OTH

Eiken Chemical Co., Ltd. (Japan)

TYO

4549

Eisai Co., Ltd. (Japan)

NAS, OSA, TYO

4523

Elementis plc (United Kingdom)

LON

ELM

Elizabeth Arden, Inc. (USA)

NAS

RDEN

EMS-Chemie Holding AG (Switzerland)

GVA, OTH, ZHR

EMS

Enaex SA (Chile)

SAN

Engro Chemical Pakistan Limited (Pakistan)

KAR

Eramet (France)

PAR, OTH

ERA

Ercros S.A. (Spain)

MAD

ECR

Estee Lauder Companies, Inc. (USA)

NYSE

EL

Eternal Chemical Co Ltd (Taiwan)

TAI

T1717

Etma Rayon Manufacturing SA (Greece)

ATH

ETMAK

Euro Med Laboratories Philippines Inc. (Philippines)

PHL

Everlight Chemical Industrial (Taiwan)

TAI

T1711

E-Z-EM, Inc. (USA)

ASE

EZM A

Fancl Corporation (Japan)

TYO

4921

Far East Pharmaceutical Technology Company Limited (Hong Kong)

HKG, OTH

Fauji Fertilizer Company (Pakistan)

KAR

Fertilizantes Fosfatados Fosfertil (Brazil)

RIO, SOP

FF4

Flugger A/S (Denmark)

CPH

FLUG-B

Forest Laboratories, Inc. (USA)

NYSE

FRX

Formosa Plastics Corp. (Taiwan)

OTH

T1301

Fujirebio Inc (Japan)

TYO

4544

Fujisawa Pharmaceutical Co Ltd (Japan)

OSA, TYO, OTH

4511

Fuller (H.B.) Company (USA)

NAS

FULL

Fumakilla Limited (Japan)

OSA

4998

Fuso Pharmaceutical Industries, Ltd. (Japan)

OSA, TYO

4538

Galen Holdings Public Limited Company (United Kingdom)

LON

GAL

Gatron Industries (Pakistan)

KAR

GenTek Incorporated (USA)

NYSE

GK

Georgia Gulf Corporation (USA)

NYSE, MSE, PBW

GGC

Giovanni Crespi S.p.A. (Italy)

ISE

CRE

Glaxo India (India)

BOM

Glaxo Wellcome p.l.c. (United Kingdom)

GLXO

Glaxo Wellcome Pakistan Ltd (Pakistan)

KAR

GlaxoSmithKline plc (United Kingdom)

OTH

GSK

Goldschmidt AG (Germany)

DUS, FRA, OTH

GOL

Grande Paroisse S.A. (France)

PAR

GPA

Great Lakes Chemical Corporation (USA)

NYSE, BSE, MSE, PBW

GLK

Groupe Finuchem (France)

PAR

FIN

Gubre Fabrikalari T.A.S. (Turkey)

IST

GUBRF

Guerbet (France)

PAR

GBT

Gujarat State Fertilizers and Chemicals Limited (India)

BOM

GUJF

Gurit-Heberlein AG (Switzerland)

GVA, ZHR

GUR

H. Lundbeck A/S (Denmark)

CPH

LUN

Hagihara Industries Inc. (Japan)

OSA

7856

Handok Pharmaceuticals Co., Ltd. (South Korea)

SEO

02390

Hanmi Pharmaceutical Co. Ltd. (South Korea)

SEO

08930

Hanwha Chemical Corporation (South Korea)

SEO

09830

Haw Par Corporation Limited (Singapore)

HKG, KUL, SIN

H02

Henkel KGaA (Germany)

DUS, FRA, OTH

HEN3

Hercules Inc. (USA)

NYSE, BSE, MSE, PBW,

HPC

Herdillia Chemicals Limited (India)

BOM

Hickson International Plc (United Kingdom)

HKSN

Hisamitsu Pharmaceutical Co., Inc. (Japan)

OSA, TYO, OTH

4530

Hodogaya Chemical Co., Ltd. (Japan)

OSA, TYO, OTH

4112

Hoechst Aktiengesellschaft (Germany)

AMS, BRU, DUS, FRA,

HOE

Hokko Chemical Industry Company Limited (Japan)

TYO

4992

Hokuriku Seiyaku Co Ltd (Japan)

OSA, TYO, OTH

4546

Honam Petrochemical Corporation (South Korea)

SEO

11170

Huaxin Cement Company, Limited (China)

SHG

CH900933

Hubei Sanonda Co. Ltd. (China)

SZN

0553

ICI India Limited (India)

BOM

ICN Pharmaceuticals, Incorporated (USA)

NYSE, MSE

ICN

Ilyang Pharmaceutical Corporation Ltd. (South Korea)

SEO

07570

Indian Petrochemical Corporation Limited (India)

BOM

Industrias Tricolor SA (Chile)

SAN

International Flavors & Fragrances Incorporated (USA)

NYSE, BSE, CIN, MSE,

IFF

International Specialty Products Incorporated (USA)

NYSE

ISP

Interphil Laboratories, Inc. (Philippines)

PHL

ILIB

Intertape Polymer Group Incorporated (Canada)

TOR, OTH

ITP

IOI Corporation Berhad (Malaysia)

KUL, SIN

IDOS

Ishihara Sangyo Kaisha, Ltd. (Japan)

OSA, TYO, OTH

4028

Israel Chemicals Limited (Israel)

TEL

ITOCHU Corporation (Japan)

OSA, TYO, OTH

8001

Ivax Corporation (USA)

ASE

IVX

IVAX-CR A.S. (Czech Republic)

PRG

JACQUES BOGART (France)

PAR

3263

Je Il Pharm. Co., Ltd. (South Korea)

SEO

Jilin Chemical Industrial Co. Ltd. (China)

HKG

Johnson & Johnson (USA)

NYSE, BSE, CIN, MSE,

JNJ

JSR Corporation (Japan)

OSA, TYO

4185

Kaken Pharmaceutical Co Ltd (Japan)

TYO

4521

Kanebo Ltd (Japan)

OSA, TYO, OTH

3102

Kansai Paint Co Ltd (Japan)

OSA, TYO, OTH

4613

Kanto Denka Kogyo Co., Ltd. (Japan)

OSA, TYO

4047

Kao Corporation (Japan)

OSA, TYO

4452

Katakura Chikkarin Company Limited (Japan)

TYO

4031

Katy Industries, Inc. (USA)

NYSE, BSE, MSE, PBW,

KT

Kemira Oy (Finland)

HEL, OTH

KRA1V

King Pharmaceuticals Incorporated (USA)

NYSE

KG

Kissei Pharmaceutical Co., Ltd (Japan)

TYO

4547

Koatsu Gas Kogyo Co., Ltd. (Japan)

OSA, TYO

4097

Koei Chemical Company, Limited (Japan)

OSA

4367

Konishi Co., Ltd. (Japan)

OSA

4956

Korea Chemical Co., Ltd. (South Korea)

10110

Korea Kumho Petrochemical Company (South Korea)

SEO

11780

Korea Petrochemical Industrial Co., Ltd. (South Korea)

SEO

06650

Kumiai Chemical Industry Company Limited (Japan)

TYO

4996

Kunsul Chemical Industrial Co. (South Korea)

SEO

00860

Kuraray Co., Ltd. (Japan)

OSA, TYO, OTH

3405

Kureha Chemical Industry Co., Ltd (Japan)

OSA, TYO

4023

Kurnia Kapuas Utama Tbk. Pt. (Indonesia)

JAK

KKGI

Kutnowskie Zaklady Farmaceutyczne Polfa (Poland)

WAR

POLFKUTN

KV Pharmaceutical Co. (USA)

NYSE

KV B

Kyorin Pharmaceutical Co., Ltd. (Japan)

TYO, OTH

4560

Kyowa Hakko Kogyo Co., Ltd. (Japan)

OSA, TYO, OTH

4151

La Seda de Barcelona, S.A. (Spain)

MAD, OTH

SED

Laboratoires Arkopharma SA (France)

PAR

ARK

Laboratorio Chile S.A. (Chile)

SAN

LABCHILE

Laporte Plc (United Kingdom)

LON

LPRT

Lenzing A.G. (Austria)

VIE

LNZ

LESCO, Inc. (USA)

NAS

LSCO

Lever Brothers (Pakistan) Ltd (Pakistan)

KAR

LG Chem Investment Limited (South Korea)

SEO

03550

Lintec Corporation (Japan)

TYO

7966

Lion Corporation (Japan)

OSA, TYO

4912

Livzon Pharmaceutical Group Inc. (China)

SZN

2513

Lonza Group AG (Switzerland)

GVA, OTH

LONN

L'Oreal (France)

PAR

OR

Lubrizol Corporation (USA)

NYSE, BSE, MSE, PBW

LZ

MacDermid Incorporated (USA)

NYSE

MRD

Malaysian Oxygen Berhad (Malaysia)

KUL

MOXB

Marbert AG (Germany)

DUS, FRA

MBT

Marine-Wendel SA (France)

PAR

MF

Martin Color-Fi, Inc. (USA)

OTC

MRCFQ

Merck KGaA (Germany)

FRA, GVA, OTH, ZHR

MRK

Millennium Chemicals Inc. (USA)

NYSE

MCH

Minerals Technologies Inc. (USA)

NYSE

MTX

Minnesota Mining & Manufacturing Co (USA)

NYSE, BSE, CIN, MSE,

MMM

Misr Chemical Industries Company (Egypt)

OTH

Mississippi Chemical Corporation (USA)

NYSE

GRO

Mitsubishi Chemical Corporation (Japan)

FRA, OSA, TYO, OTH

4010

Mitsubishi Gas Chemical Co., Inc. (Japan)

OSA, TYO, OTH

4182

Mitsubishi Rayon Co Ltd (Japan)

OSA, TYO, OTH

3404

Mitsui Chemicals Incorporated (Japan)

OSA, TYO

4183

Mochida Pharmaceuticals Co Ltd (Japan)

TYO

4534

Montefibre S.p.A. (Italy)

ISE

MF

Mylan Laboratories Inc. (USA)

NYSE, BSE, MSE, PCS

MYL

Namhae Chemical Corporation (South Korea)

SEO

25860

National Organic Chemical Industries (India)

BOM

National Petrochemical Public Co Limited (Thailand)

BAN

NPC

Nature's Sunshine Products, Inc (USA)

NAS

NATR

NBTY Inc. (USA)

NAS

NBTY

Nicca Chemical Co., Ltd. (Japan)

OTH

4463

Nichias Corporation (Japan)

OSA, TYO

5393

Nihon Nohyaku Co Ltd (Japan)

TYO

4997

Nihon Parkerizing Co., Ltd. (Japan)

OSA, TYO

4095

Nikken Chemicals Co., Ltd. (Japan)

TYO

4529

Nippon Carbide Industries Co., Inc. (Japan)

OSA, TYO

4064

Nippon Chemical Industrial Co., Ltd. (Japan)

OSA, TYO, OTH

4092

Nippon Kayaku Co Ltd (Japan)

OSA, TYO, OTH

4272

Nippon Paint Co., Ltd. (Japan)

OSA, TYO, OTH

4612

Nippon Sanso Corporation (Japan)

OSA, TYO, OTH

4091

Nippon Shinyaku Co., Ltd. (Japan)

OSA, TYO, OTH

4516

Nippon Shokubai Company Limited (Japan)

OSA, TYO, OTH

4114

Nippon Soda Co., Ltd. (Japan)

OSA, TYO, OTH

4041

Nippon Synthetic Chemical Industry Co. (Japan)

OSA, TYO, OTH

4201

Nissan Chemical Industries Ltd (Japan)

OSA, TYO, OTH

4021

Nitto Denko Corporation (Japan)

OSA, TYO, OTH

6988

Nitto FC Co., Ltd. (Japan)

OTH

4033

NOF Corporation (Japan)

OSA, TYO, OTH

4403

Norsk Hydro ASA (Norway)

NYSE, DUS, FRA, LON,

NHY

Nova Chemicals Corpn (Canada)

BSE, CIN, PCS, MON,

NCX

Novartis AG (Switzerland)

FRA, OTH

NOVN

Novartis India Limited (India)

OTH

Novo Nordisk As (Denmark)

CPH, OTH

NOVO-B

Novozymes A/S (Denmark)

CPH

Nufarm Limited (New Zealand)

MBE, NZL, SYD, OTH

FER

Nutraceutical International Corp (USA)

NAS

NUTR

NutraMax Products, Inc. (USA)

OTC

NMPCQ

Octel Corporation (USA)

NYSE

OTL

Olin Corporation (USA)

NYSE, BSE, CIN, MSE,

OLN

OM Group, Inc. (USA)

NYSE

OMG

OMNOVA Solutions Incorporated (USA)

NYSE, BSE, CIN, PCS

OMN

Ono Pharmaceutical Co Ltd (Japan)

OSA, TYO

4528

Oriental Chemical Ind. Co., Ltd. (South Korea)

SEO

02740

Orion Group (Finland)

OTH

ORIBS

Osaka Sanso Kogyo Ltd (Japan)

OSA, TYO, OTH

4089

Pacific Corporation (South Korea)

SEO

02790

Palmco Holdings Berhad (Malaysia)

KUL, SIN

PCHS

Paterson Zochonis Plc (United Kingdom)

TOR, LON

PATZ

Patheon Inc (Canada)

TOR

PTI

Perbio Science AB (Sweden)

STO

PBIO

Perrigo Company (USA)

NAS

PRGO

Perstorp AB (Sweden)

LON, STO

PERS-B

Pliva-Lachema A.S. (Czech Republic)

PRG

Polifarb Cieszyn-Wroclaw S.A. (Poland)

WAR

POLIFARBC

Polyone Corp (USA)

NYSE

POL

PPG Industries Inc (USA)

NYSE, BSE, MSE, PBW,

PPG

Prodef SA (France)

PAR

3817

Produits Chimiques Auxiliares et de Synthese (France)

PAR

PCA

Przedsiebiorstwo Farmaneutyczne Jelfa Spolka Akcyina (Poland)

WAR

JELFAA

PT Unilever Indonesia Tbk (Indonesia)

JAK

UNVR

Quaker Chemical Corporation (USA)

NYSE

KWR

Raisio Group PLC (Finland)

HEL

RAIVV

Rasa Industries, Ltd. (Japan)

OSA, TYO, OTH

4022

Reckitt and Colman of India Limited (India)

BOM

RC

Reckitt Benckiser PLC (United Kingdom)

LON

RB

Recordati Industria Chimica e Farmaceutica SpA (Italy)

ISE

RECNC

Renner Herrmann S.A. (Brazil)

RIO, SOP

RH4

Rhodia (France)

PAR

RHA

Richter Gedeon Vegyeszeti Gyar Rt. (Hungary)

FRA, LON, BUD

Riken Vinyl Industry Co., Ltd. (Japan)

TYO, OTH

4220

RINOL AG (Germany)

FRA

RIL

Roche Holding AG (Switzerland)

GVA

ROG

Rohto Pharmaceutical Co., Ltd. (Japan)

OSA, TYO

4527

RPM, Inc. (USA)

NYSE

RPM

S.T. Chemical Co., Ltd. (Japan)

TYO

4951

SA d'Explosifs et de Produits Chimique (France)

PAR

3902

Sakai Chemical Industry Co., Ltd. (Japan)

OSA, TYO

4078

Sam Hwa Paints Industrial Co., Ltd. (South Korea)

SEO

00390

Samsung Fine Chemicals Co., Ltd. (South Korea)

SEO

04000

Sankyo Company, Limited (4501) (Japan)

OSA, TYO, OTH

4501

Sanofi-Synthelabo (France)

PAR

SAN

Santen Pharmaceutical Company Limited (Japan)

OSA, TYO

4536

Sanyo Chemical Industries Ltd (Japan)

OSA, TYO, OTH

4471

Sarna Kunststoff Holding AG (Switzerland)

ZHR

SAKN

SASA Suni ve Sentetik Elyaf Sanayii A.S. (Turkey)

IST

SASA

Sasol Limited (South Africa)

JNB

SOL

Schering Aktiengesellschaft (Germany)

DUS, FRA, GVA, LON,

SCH

Schering-Plough Corporation (USA)

NYSE, BSE, CIN, MSE,

SGP

Schwarz Pharma AG (Germany)

DUS, FRA

SRZ

Serono SA (Switzerland)

GVA, OTH, ZHR

AREB

Shandong Xinhua Pharmaceutical Company Limited (China)

HKG

Shin-Etsu Chemical Co., Ltd. (Japan)

OSA, TYO, OTH

4063

Shionogi & Co., Ltd (Japan)

OSA, TYO, OTH

4507

Showa Denko Kabushiki Kaisha (Japan)

OSA, TYO, OTH

4004

Showa Highpolymer Co., Ltd. (Japan)

OSA, TYO

4214

Sico Inc. (Canada)

TOR

SIC

Siegfried AG (Switzerland)

ZHR

SFZN

Sigma-Aldrich Corporation (USA)

NAS

SIAL

Sika Finanz AG (Switzerland)

GVA, OTH, ZHR

SIK

Sinclair (William) Holdings Plc (United Kingdom)

LON

SNCL

Sinopec Yizheng Chemical Fibre Co. Ltd. (China)

HKG

SKW Trostberg AG (Germany)

SKW

Slovakofarma a.s. (Slovakia)

BRT

SmithKline Beecham Plc (United Kingdom)

SB

Snia (Italy)

FRA, ISE, OTH

SN

Solutia Inc. (USA)

NYSE

SOI

Solvay Societe Anonyme (Belgium)

AMS, BRU, DUS, FRA,

SOL

SP Group A.S. (Denmark)

CPH

HYG

SSL International Plc (United Kingdom)

LON

SSL

SSP Company Limited (Japan)

TYO

4537

Stada Arzneimittel AG (Germany)

FRA

SAZ3

Stepan Company (USA)

NYSE

SCL

Sumitomo Bakelite Co Ltd (Japan)

OSA, TYO, OTH

4203

Sumitomo Chemical Company, Limited (Japan)

OSA, TYO, OTH

4005

Sumitomo Seika Chemicals Company, Limited (Japan)

OSA, TYO

4008

Sunstar Inc. (Japan)

OSA

4913

Swallowfield Plc (United Kingdom)

LON

SWL

Syncor International Corporation (USA)

NAS

SCOR

Syngenta AG (Switzerland)

OTH

Taekwang Industries Co., Ltd. (South Korea)

SEO

03240

Taisho Pharmaceutical Co., Ltd. (Japan)

OSA, TYO

4535

Taiyo Toyo Sanso Co., Ltd. (Japan)

OSA, TYO

4103

Takeda Chemical Industries, Ltd. (Japan)

OSA, TYO, OTH

4502

Tanabe Seiyaku Co Ltd (Japan)

OSA, TYO, OTH

4508

Teijin Limited (Japan)

OSA, TYO, OTH

3401

Teikoku Hormone Mfg. Co., Ltd. (Japan)

TYO

4514

Tenma Corporation (Japan)

TYO

7958

Terra Industries Incorporated (USA)

NYSE, BSE, MSE, PCS,

TRA

Tetra Technologies, Inc. (USA)

NYSE

TTI

Teva Pharmaceutical Industries Ltd. (Israel)

TEL

TEVA

Thai Plastic and Chemical Public Company Limited (Thailand)

BAN

TPC

The BOC Group plc (United Kingdom)

LON

BOC

The Body Shop International PLC (United Kingdom)

LON

BOS

The Clorox Company (USA)

NYSE, BSE, CIN, MSE,

CLX

The Procter & Gamble Co(P&G) (USA)

NYSE, BSE, CIN, MSE,

PG

The Scotts Company (USA)

NYSE

SMG

Tianjin Capital Environmental Protection Company Limited (China)

HKG

Ticor Limited (Australia)

SYD

TOR

Toagosei Co., Ltd. (Japan)

OSA, TYO, OTH

4045

Toho Chemical Industry Company, Limited (Japan)

TYO

4409

Tokai Carbon Co., Ltd. (Japan)

OSA, TYO, OTH

5301

Tokuyama Corporation (Japan)

OSA, TYO, OTH

4043

Tokyo Ohka Kogyo Co., Ltd (Japan)

TYO

4186

Tokyo Printing Ink Mfg. Co., Ltd. (Japan)

TYO

4635

Tokyo Tanabe Co., Ltd. (Japan)

4532

Toray Industries, Inc. (Japan)

DUS, FRA, LON, OSA,

3402

Torii Pharmaceutical Co., Ltd. (Japan)

TYO

4551

Tosoh Corporation (Japan)

OSA, TYO, OTH

4042

Toyama Chemical Co., Ltd. (Japan)

OSA, TYO

4518

Toyo Ink Manufacturing Co Ltd (Japan)

TYO

4634

Toyobo Co Ltd (Japan)

OSA, TYO, OTH

3101

Toyoda Gosei Co Ltd (Japan)

OTH

7282

UBE Industries Ltd (Japan)

OSA, TYO, OTH

4208

UCB SA (Belgium)

BRU

UCB

Uralita S.A. (Spain)

BCN, MAD

URA

Valhi Incorporated (USA)

NYSE, PBW

VHI

Valspar Corp. (USA)

NYSE

VAL

Ve Wong Corp (Taiwan)

TAI

T1203

Virbac (France)

PAR

VIR

Watson Pharmaceuticals Inc (USA)

NYSE

WPI

Weider Nutrition International, Inc. (USA)

NYSE

WNI

Welfide Corp. (Japan)

OSA, TYO, OTH

4509

Wella AG (Germany)

DUS, FRA, GVA, VIE,

WAD3

Wellman Incorporated (USA)

NYSE

WLM

Yamanouchi Pharmaceutical Co Limited (Japan)

OSA, PAR, TYO

4503

Yorkshire Group plc (United Kingdom)

LON

YOR

Yuhan Corporation (South Korea)

SEO

00100

Yule Catto & Co. plc (United Kingdom)

LON

YULC

ZEON Corporation (Japan)

OSA, TYO, OTH

4205

Zeria Pharmaceutical Co., Ltd. (Japan)

TYO

4559

Based on this list, the ratios discussed in Stage 3 are calculated for every firm, and then averaged to create global benchmarks. No weighting is used in this average.

Stage 6. Projection of Deviations. The goal of this report is not to present the raw ratios or averages, but to present the difference between the company’s estimated ratio and the projected global average for that same ratio. Furthermore, it can be insightful to know the location of each ratio within the distribution of the companies used in Stage 5. These deviations, in fact, can be seen as projections or likely scenarios for the future. This is often true for two reasons. First, while a company’s financials change from year to year, its ratios are often stable. This is especially true for the global benchmarks which represent averages across many companies. From a purely Bayesian sense, the difference between the company’s recent ratios and the benchmarks are a reasonable prior for future deviations. This is true, even if the entire industry is hit by an external or exogenous shock, such as an oil crisis or economic slowdown. In other words, I assume that the structure of the variance in the industry’s financials remains stable. Second, many of the data are based on preliminary reports that might be changed in future filings. As forecasts, therefore, the numbers derived from these are also forecasts of past and future performance (with associated uncertainties). The calculation of the difference between a company's ratios and the global benchmarks is meant to yield roughly approximate forecasts, or "useful measures". Again, the forecasts are based on the assumption of relative stability. This assumption has proven extremely robust in previous applications of this methodology (i.e. today’s weather is a good predictor of tomorrow’s weather, but not the weather three years from now).

Stage 7. Projection of Ranks and Percentiles. Based on the calculation of deviations, relative ranks and percentiles are calculated across the firms used in the global benchmarks. The percentile estimates the percent of firms within the same sector of the global economy that have values of the ratio lower than the firm in question. It is important to note that a percentile being high (or low) does not mean good (or bad) past, present or future financial performance. The reader must draw this conclusion on his own. The estimates provided were created to provide managerial insight, and not a recommendation with respect to any valuation of the company or its management.

I graphically report, for each part of the financial statement, the larger structural differences between the firm and the global benchmarks, and provide a summary table of ranks and percentiles. A deviation from the global norm need not be a bad sign. Rather, it is simply a substantial difference that might merit further attention or perhaps signal a firm’s relative strength or weakness for the coming fiscal year.

LIMITATIONS AND EXTENSIONS

Shim and Siegal (p. 60) stress that “while ratio analysis is an effective tool for assessing a company’s financial condition, its limitations must be recognized.” In particular, they find that (p. 59) “no single ratio or group of ratios is adequate for assessing all aspects of a company’s financial condition.” The authors note the following limitations associated with ratio analyses which apply to the global benchmarking and vertical analysis presented here (p.60):

  • Accounting standards or policies may limit useful comparisons across companies

  • Management accounting practices across companies and countries may not be performed in the same style

  • Ratios are static and do not reveal future trends

  • Ratios do not indicate the quality of the components used to calculate the ratios (i.e. ratios have ambiguous interpretations)

  • Reported ratios may not reflect real values

  • Companies may be highly diversified, limiting the comparability of their ratios to others

  • Industry averages or norms are approximate; finer industry definitions may be required for certain interpretations or comparisons

  • Financial statements and resulting ratios often mean different things to different people depending on their points of view or motivations.

Again, all figures reported here are estimates, so due caution is required. The above caveats, and the fact that statements made in this report are forward-looking, requires that this point be emphasized. A number of intervening factors can have material effect on the ratios and variances forecasted. These include changes in a company's management style, exchange rate volatility, changes in accounting standards, the lack of oversight or comparability in accounting standards, changes in economic conditions, changes in competition, changes in the global economy, changes in source data quality, and similar factors. Please refer to Chapter 6 for further caveats.

A useful extension of the analysis presented here is to consider only a small subset of firms that compete more directly with the company in question, or its immediate suppliers or buyers (in the case of value chain analysis). Choosing this set of competitors or value-chain players may, however, be a very subjective task. While one can rely on public statements made from the firm itself about who it believes its competitors, buyers, or suppliers to be, an external analyst may have a very different opinion. ICON Group is able to generate additional reports that can benchmark any given company, including the one profiled here, against any combination of firms drawn from a pool of over 20,000 domestic and international companies. Should the reader wish a similar report to the one presented here, but for a very particular definition of company and benchmarks, please contact us via email with your request, at . Please indicate the "target firm", and the "benchmark firms" that should be included in the pool to comprise the average benchmarks. ICON Group will quickly report back the feasibility of such a study. The turnaround for these requests is often only a few days, and the price of these reports is comparable to this report.

 Skim and Siegel (2000), Financial Management published by Barron’s Educational Series, Inc. (BARON’S BUSINESS LIBRARY Series), ISBN: 0-7641-1402-6.

  • Search:
  • Additional links you may find of interest: